PT79320B - Process for the preparation of an occlusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin - Google Patents

Process for the preparation of an occlusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin Download PDF

Info

Publication number
PT79320B
PT79320B PT79320A PT7932084A PT79320B PT 79320 B PT79320 B PT 79320B PT 79320 A PT79320 A PT 79320A PT 7932084 A PT7932084 A PT 7932084A PT 79320 B PT79320 B PT 79320B
Authority
PT
Portugal
Prior art keywords
nitroxymethyl
chloropyridine
cyclodextrin
occlusion
preparation
Prior art date
Application number
PT79320A
Other languages
English (en)
Other versions
PT79320A (en
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of PT79320A publication Critical patent/PT79320A/pt
Publication of PT79320B publication Critical patent/PT79320B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

Descrição do objecto do invento que
FUJISAWA PHARMACEUTICAL CO.,ITD japonesa, industrial, com sede em NP 3,4-chome, Doshomachi, Hi gashi-Ku, Osaka, Japão, pretende obter em Portugal, para: "PROCESSO PARA A PREPARAÇÃO DE UM COMPOSTO DE OCLUSÃO DE 2_NI_ TR0XXMETIL-6-CL0R0PIRIDINA COM P -CICLODEXTRINA".
0 presente invento refere-se a um proces Iso para a preparação de um composto de oclusão de 2_nitroximefcil-6-cloropiridina com ft-ciclopiridin.·.
A 2_nitroximetil-6-cloropiridina é um omposto que possui a fórmula estrutural apresentada a servir é útil como medicamento para o tratamento de perturbações asculares.
CH 0N0„ 2 2
Λ 2-nitroximetil-6~cloropiridina é uma lubstância oleosa e volátil. De uma maneira geral, é difícil /onverter esta substância numa preparação farmacêutica.
Como resultado do estudo intenso conduzi, o de modo a ultrapassar a dificuldade anteriormente referida, erificou-se que a dificuldade podia ser ultrapassada pela con
55.780
MES/ERU/8E-1254
versão de 2-nitroximetil-6-cloropiridina no sen composto tle oclusao comβ-ciclodextrina numa porporção molar de cerca de 1:1 ou cerca de 3:1.
Assim, o presente invento resolveu com sucesso não apenas o problema da formação de uma preparação em pó de 2-nitroximetil-A_cloropiridina mas também o problema de impedir a sua volatilização.
0 processo para a preparação do presente invento é efectuado por meio da reacção de 2_nitroximetil-6_ -cloropiridina Com fi-ciclodextrina.
0 processo de oclusão inclui diversas mo. dificações. Por exemplo, existem um processo para a preparação de um solvente, um processo que compreende a mistura do composto base e os compostos adicionais juntamente com uma pequena quantidade de um solvente, etc. Destes processos, o que se pre fere é o processo para a preparação do solvente que requer ape nas que se misturem ambos os compostos entre si num solvente apropriado. 0 composto de oclusão, tal como foi obtido, é isolado e purificado de uma maneira convencional. Por exemplo, quando se efectua a reacção de oclusão numa solução aquosa, o composto de oclusão, que ê levemente solúvel em água, c retirado por precipitação na mistura de reacção, Fode separar-se o precipitado por meio de um método convencional, por exemplo, por centrifugação. 0 produto assim separado pode ,ser purificado mediante lavagem com água, pelo que se retira afi -ciclodex trina solúvel em água ou a 2-nitroximetil-6-cloropiridina.
0 composto de oclusão obtido pelo proces
55.780
MES/ERU/8E-1254
so anteriormente descrito caracteriza-se por evitar a volatilização de 2_nitroximetil-6-cloropiridina. For exemplo, tal como é'tornado evidente pela Fig, 5, que apresenta a percenta-. gem da 2-nitroximetil-6-cloropiridina residual em função do tempo, 100% do composto de oclusão de 2-nitroximetil_6-cloro_ piridina- -ciclodextrina numa proporção molar de lí1 ou cerca de 87% de 2-nitroximetil_6_cloropiridina-p -ciclodextrina numa proporção molar de 3’·!, permanece depois de repousar durante 60 minutos enquanto que, com 2-nítroximetil-6-cloropiri. dina por si, a percentagem residual, após 60 minutos, é de 0%, Como se tornou evidente, a volatilização de 2-nitroximetil-6-oloropiridina é largamente evitada.
0s exemplos que se seguem são ainda representativos do processo para a preparação do presente inven to.
Exemplo 1
Em cada um de cinco tubos de centrifugação, dissolveram-se 600 mg de β -ciclodextrina em 20 ml de água destilada. Após a adição de Ç0, ICC, £00, 300 e 400 mg de
2-nitroximetil-6-cloropiridina aos cinco tubos de centrifugação, respectivamente, agitaram-se as misturas, centrífugaram_ -se e deixaram-se repousar durante a noite à temperatura ambiente para se completar a cristalização.
Recolheram-se os cristais por filtração, lavaram-se com água e secaram-se ao ar para proporcionarem um composto de oclusão de 2-nitroximetil-6-cloropiridina com β -ciclodextrina·
-3
55.780
MES/ERU/8E-1254
As condiçoes para a preparação do compos
to de oclusão de 2-.nitroximetil-6-eloropiridina com β -Ciclodextrina e as proporções molares que se verificarem nos produtos são apresentados no Quadro 1.
0 composto de oclusão obtido possui as seguintes caracteristicas físicas.
(i) No seu modelo de difracção de pó obtido por raio X, apresenta pontos máximos de cerca de 11,5°, cerca de 17,2° e cerca de 18,4°, que caracterizam um composto de oclusão de 2_nitroximetil-6-cloropiridina com β-ciclodextrina.
(ii) No seu espectro de absorção de infravermelhos (Nujol), apresenta absorções a 3300, 1645, 1586, 1568, 1459, 1376, 1 330, 1281, 1158, 1080, 1022, 1000, 940 e 842 cm"1
(iii) É levemente solúvel em água.
-Z|_
ff1"1"'
55,780
MES/ERU/8E.1254
to
©
íd
H
O
cí
Q
<
3>
w
©
io
o
íd
O
a
0
íd
a
©
o
t«0
«5
3
rt
0
0
V
Ό
O
P
to
o
a
ε
o
o
©
•b
0
1(0
o>
(0
íd
to
a
©
íd
0,
to
(0
3
(0
a
to
©
10
O"
rt
Ό
C
O
υ
1 ίο—-
0 Ό Ο
H i Ό
0 Ο rt
•Η I Ρ Ρ
O rt to χ
1 rt Ο Ο
a ε ·η
ê Ο Ο
0 -rl Ό X Ο Ρ
0 Ο Ο
íd íd c ε ο rt
<0 P C •
rt rt (0 0 ▼Η τΜ rH cn ΓΗ
0 C ε t C •Η Η rrt τΗ ν-4
C4 Ό (0
0 \ •Η 4^
ICO nj íd
o" c •Η Ο
fd eH ai«
0 íd ο to
a ρ G 3
0 X Ο rt
u V rt Ο
rt Ό Ο Ο
Ο
(0 1(0
c to
•rf 3
1 Ό ρΗ
•Η ·Η 0
X t, 0
0 «rl íd a 0
P 0 Ό ζ-Χ tn tn 00 rt
•H • • • •
C 0 Ο tn Ή* +C Tf· rt·
| H csj 0 «Ρ <0 τ-4 ^rt Ή rt cn
1 0
© vc a
Ό 1 ε ο
rH Ο Ό
Ϊμ ·Η Ο rt
0 P Ρ
© 4) Ο ρ
η ε C Ο
1 rt π}
4) rt C Ό Ρ rt
€ Ό
4) 2 rt ·. Ό rt t, ho (0 X rt ε Ο Ο Ο ο ο
ό ο a-~ ιη ο ο ο ο
rt U Ο Ρ P rt C rt O (0 C 1 3 i 'C rt | Ί-Ρ rt ΓΌ Tf·
(0
t»
3 (0
P c
B s-' rt
•rl Π3 ε ό í. p
X
ε —ι 4)
V rt Ό
Ρ O
0 to rt
1(0 © O
σ> Ό •rf
3 O
rt (0 1
0 £?
w 5 Ο
'(0 hO ο
(β β ε VC
Ό V Ό
Ό
0 © (0
1(0 rt Ό Ό
ο" ε (0 (0
•Η Ό C
(0 ο rt Ο
Ο C4 ρ rt
a C Ο
ε ε (0 rt
Ο 4) 3 Ό
ΑΕΖαε .....Οί <ΰ
5
55.780
MES/ERU/8E-1254
por raios
e os seus
tados nas
Os modelos de difração de pó obtidos X destes produtos são apresentados nas Figuras 1 e 2 espectros de absorção de infravermelhos são apresenFiguras 3 e 4.
Breve descrição dos desenhos.
As Figuras 1 e 2 apresentam modelos de difracçao de pós dos compostos de oclusão obtidos no Exemplo 1 de acordo com o presente invento, nomeadamente os compostos de oclusão de 2_nitroximetil-6-cloropiridina com -ciclodextrina nos racios molares de 1:1 e 3:1, respectivamente, e as Figuras 3 e 4 apresentam espectros de absorção de infravermelhos dos compostos de oclusão de acordo com o presente invento nas proporções molares de 1:1 e de 3:1, respectivamente.
fi
A Figura 5 ilustra a influência da oclu sao na volatilização da 2-nitroximetil-6-cloropiridina.
0 depósito do primeiro pedido para o in vento acima descrito foi efectuado no Japão, em 11 de Outubro de 1983 sob ο N2. 190345/1983.
-

Claims (1)

  1. REIVINDICAÇÕES1?. _ Processo para a preparação de um composto de oclusão de 2_nitroximetil-6-cloropiridina com^ -ciclodextrina que compreende a reacção de 2_nitroximetil-6-cloropiridina com /? -ciclodextrina.
    23. - Processo de acordo com a reivindicação 1, caracterizado pelo facto de se incorporar uma solu
    55.780
    MES/ERU/8E-1254
    ção aquosa dina.
PT79320A 1983-10-11 1984-10-04 Process for the preparation of an occlusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin PT79320B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58190345A JPS6081166A (ja) 1983-10-11 1983-10-11 ２−ニトロオキシメチル−６−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法

Publications (2)

Publication Number Publication Date
PT79320A PT79320A (en) 1984-11-01
PT79320B true PT79320B (en) 1986-09-08

Family

ID=16256648

Family Applications (1)

Application Number Title Priority Date Filing Date
PT79320A PT79320B (en) 1983-10-11 1984-10-04 Process for the preparation of an occlusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin

Country Status (18)

Country Link
US (1) US4575548A (pt)
EP (1) EP0141300A3 (pt)
JP (1) JPS6081166A (pt)
KR (1) KR850003414A (pt)
CN (1) CN85102133A (pt)
AU (1) AU576521B2 (pt)
CA (1) CA1248523A (pt)
DK (1) DK461184A (pt)
ES (1) ES536654A0 (pt)
FI (1) FI843944L (pt)
GR (1) GR80531B (pt)
HU (1) HU194285B (pt)
IL (1) IL73076A (pt)
NO (1) NO843773L (pt)
OA (1) OA07832A (pt)
PH (1) PH20203A (pt)
PT (1) PT79320B (pt)
ZA (1) ZA847350B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
JPS60202115A (ja) * 1984-03-27 1985-10-12 Ichiro Shibauchi エポキシ樹脂用硬化剤
ZA885069B (en) * 1987-07-24 1989-03-29 Fujisawa Pharmaceutical Co Sustained-release percutaneous preparations
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
EP1176792A1 (en) * 2000-07-24 2002-01-30 Alcatel Method and apparatus for providing an all digital loop with power-optimised mode
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010478A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070009531A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US12108939B2 (en) 2008-06-17 2024-10-08 Boston Scientific Scimed, Inc. Endoscopic tissue grasping systems and methods
US11812951B2 (en) 2008-06-17 2023-11-14 Apollo Endosurgery Us, Inc. Endoscopic needle assembly
CA2692211C (en) * 2009-12-14 2011-09-13 Cellresin Technologies, Llc Maturation or ripening inhibitor release from polymer, fiber, film, sheet or packaging
ES2552656T3 (es) 2011-03-27 2015-12-01 Cellresin Technologies, Llc Composiciones, artículos y métodos a base de ciclodextrina
US10182567B2 (en) 2011-03-27 2019-01-22 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
US9320288B2 (en) 2012-11-30 2016-04-26 Cellresin Technologies, Llc Controlled release compositions and methods of using
US9421793B2 (en) 2014-06-26 2016-08-23 Cellresin Technologies, Llc Electrostatic printing of cyclodextrin compositions
US11051800B2 (en) 2016-08-10 2021-07-06 Apollo Endosurgery Us, Inc. Endoscopic suturing system having external instrument channel

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2959580A (en) * 1956-10-17 1960-11-08 Univ Minnesota Formation of inclusion compounds
CH445129A (fr) * 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS57142962A (en) * 1981-02-28 1982-09-03 Santen Pharmaceut Co Ltd Cyclodextrin clathrate compound of sulfur-containing compound
JPS6054304B2 (ja) * 1981-10-16 1985-11-29 株式会社バコム ジソピラミド包接化合物
US4425336A (en) * 1982-05-24 1984-01-10 Key Pharmaceuticals, Inc. 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes
DK311683A (da) * 1982-07-26 1984-01-27 Fujisawa Pharmaceutical Co Fremgangsmaade til fremstilling af pyridylalkylnitratforbindelser
JPS6025967A (ja) * 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
DE3329517A1 (de) * 1983-08-16 1985-02-28 Hoechst Ag, 6230 Frankfurt Einschlussverbindung von n,n-dimethyl-2-chlor-5-(3-methyl-2-(phenylimino)-4-thiazolin-4-yl)phenylsulfonamid, verfahren zu ihrer herstellung sowie pharmazeutische praeparate
DE3337802A1 (de) * 1983-10-18 1985-04-25 Merck Patent Gmbh, 6100 Darmstadt Pharmazeutische zubereitung

Also Published As

Publication number Publication date
ES8506758A1 (es) 1985-08-01
DK461184A (da) 1985-04-12
JPS6245226B2 (pt) 1987-09-25
JPS6081166A (ja) 1985-05-09
EP0141300A3 (en) 1986-01-29
FI843944A7 (fi) 1985-04-12
PH20203A (en) 1986-10-20
KR850003414A (ko) 1985-06-17
FI843944A0 (fi) 1984-10-08
GR80531B (en) 1985-01-09
AU3339984A (en) 1985-04-18
PT79320A (en) 1984-11-01
US4575548A (en) 1986-03-11
FI843944L (fi) 1985-04-12
ES536654A0 (es) 1985-08-01
OA07832A (fr) 1986-11-20
DK461184D0 (da) 1984-09-26
CN85102133A (zh) 1987-01-17
AU576521B2 (en) 1988-09-01
HU194285B (en) 1988-01-28
NO843773L (no) 1985-04-12
ZA847350B (en) 1985-10-30
IL73076A0 (en) 1984-12-31
HUT36832A (en) 1985-10-28
EP0141300A2 (en) 1985-05-15
CA1248523A (en) 1989-01-10
IL73076A (en) 1988-05-31

Similar Documents

Publication Publication Date Title
PT79320B (en) Process for the preparation of an occlusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin
EP0117570B1 (en) Sodium salt of ursodeoxycholic sulphate
US3951949A (en) Sulfates of hydroxyethyl starch
PT93488B (pt) Processo de preparacao de composicoes farmaceuticas a base de (7 alfa, 17 alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5(10)-en-20-in-3-ona e destes compostos numa forma pura e cristalina
PT95961B (pt) Processo para a preparacao de heparinas supersulfatadas
KR0173480B1 (ko) 베타-시클로덱스트린 유도체의 폴리술페이트 및 그의 제조방법
US4663348A (en) Furosemide salts and pharmaceutical preparations thereof
US5079237A (en) Inclusion complex of nicardipine or its hydrochloride with beta-cyclodextrin and a sustained release pharmaceutical preparation containing the same
US5198430A (en) Inclusion complexes with silybinin, their preparation and pharmaceutical compositions containing them
FR2413389A1 (fr) Composes a tete de pont azotee ayant une action anti-allergique et procede pour leur preparation
CA1132561A (en) Hydroxy pyrimidine derivatives
US2923704A (en) Cycloamylose sulfates and derivatives thereof
JP2001509487A (ja) ペプチケミオを含有する薬剤学的組成物
Raper Some problems of tyrosine metabolism
EP0184248A2 (en) Salts of 5&#39;-methylthio-5&#39;-deoxyadenosine with long-alkyl chain sulphonic acids
JPH07149784A (ja) シクロマルトオリゴ糖のスルホン化誘導体、その製造方法及びこれらの誘導体を含む活性物質用担体
US2666066A (en) Ethylenediamine salts of cyclopen-tanopolyhydrophenanthrene-3-monosulfates
EP1272531B8 (en) Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds
EP0338092A1 (en) Anti-hiv agent
NO148947B (no) Apparat for paafoering av et flytende bindemiddel.
Folkers et al. Erythrina Alkaloids. XVIII. Studies on the Structure of Erysopine, Erysodine, Erysovine and Erythraline
Bogert et al. The synthesis of 6-hydroxypiperonylic acid and incidental compounds
EP0326262A3 (en) Clathrate compound and a method of producing the same
CA1069507A (en) Compound, named n-oxy-ajmaline, the method of preparing it and its application in therapeutics
EP0007159B1 (en) A chloral derivative; method for preparing this derivative and a therapeutic composition containing this derivative